Hecquet B, Caty A, Fournier C, Lefebvre J L, Adenis L
Laboratoire de Pharmacodynamie Clinique, Centre Oscar-Lambret, Lille, France.
Bull Cancer. 1987;74(4):433-6.
Tumour tissue levels of platinum were determined in patients with head and neck tumours receiving carboplatin (11 patients, 400 mg/m2) and iproplatin (5 patients, 360 mg/m2). The platinum concentrations ranged from 1.1 +/- 0.4 ng Pt/mg tissue (iproplatin administration) to 1.4 +/- 0.3 ng Pt/mg tissue (carboplatin administration). These results were compared with published platinum levels after cisplatin administration. Although the administered dose of carboplatin (1.08 mmol/m2) and iproplatin (0.86 mmol/m2) was higher than the cisplatin one (0.33 mmol/m2), no significant statistical differences were observed in the resulting platinum tissue levels. The constancy of tumour platinum level after treatment with different platinum complexes could be explained, at least for carboplatin and cisplatin, by both the tumour diffusion properties and the reactivity of the drugs.
对接受卡铂(11例患者,400mg/m²)和异丙铂(5例患者,360mg/m²)治疗的头颈部肿瘤患者的肿瘤组织铂水平进行了测定。铂浓度范围为1.1±0.4ng Pt/mg组织(异丙铂给药)至1.4±0.3ng Pt/mg组织(卡铂给药)。将这些结果与已发表的顺铂给药后的铂水平进行了比较。尽管卡铂(1.08mmol/m²)和异丙铂(0.86mmol/m²)的给药剂量高于顺铂(0.33mmol/m²),但在所得的铂组织水平上未观察到显著的统计学差异。用不同铂络合物治疗后肿瘤铂水平的稳定性,至少对于卡铂和顺铂而言,可以通过肿瘤扩散特性和药物反应性来解释。